Ekso Bionics Holdings, Inc.
(NASDAQ : EKSO)

( )
EKSO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
MDTMedtronic PLC
0.28%79.480.6%$434.38m
ALGNAlign Technology, Inc.
-0.40%253.896.3%$328.02m
ISRGIntuitive Surgical, Inc.
-0.34%392.482.5%$321.07m
TMOThermo Fisher Scientific Inc.
-0.23%190.171.0%$309.97m
ABTAbbott Laboratories
0.02%55.550.8%$299.23m
BDXBecton, Dickinson and Company
-0.55%220.301.3%$280.16m
EWEdwards Lifesciences Corporation
-0.01%107.091.2%$203.10m
BSXBoston Scientific Corporation
-0.09%28.261.1%$192.76m
SYKStryker Corporation
-0.69%155.401.3%$184.57m
ZBHZimmer Biomet Holdings, Inc.
-0.62%111.551.7%$164.77m
BAXBaxter International Inc.
-1.75%63.851.7%$163.38m
BCRC. R. Bard, Inc.
-0.28%333.331.6%$149.53m
XRAYDENTSPLY International Inc.
0.55%67.553.0%$139.79m
HOLXHologic, Inc.
0.60%39.961.7%$120.77m
WATWaters Corporation
-0.69%198.233.3%$100.85m

Company Profile

Ekso Bionics Holdings, Inc. designs, develops and sells wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets. The company operates through the following segments Medical Devices, Industrial Sales, and Engineering Services. The Medical service segment designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The Industrial Sales segment designs, engineers, commercializes, and sells exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The Engineering services segment engages in research and development service arrangements, technology license agreements, and government grants. Ekso Bionics Holdings was founded on January 30, 2012 and is headquartered in Richmond, CA.